The DOI matches its Crossref record; 405 of the 406 references it cites were found in a registry or an index.
Reduced Vancomycin Susceptibility in Staphylococcus aureus , Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
Open accessAbstract
SUMMARY: The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms. Recent data show that these strains have been detected globally and in many cases are associated with glycopeptide treatment failure; however, more rigorous clinical studies are required to clearly define the contribution of hVISA to glycopeptide treatment outcomes. It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary. Interestingly, changes in the staphylococcal surface and expression of agr are likely to impact host-pathogen interactions in hVISA and VISA infections. Given the subtleties of vancomycin susceptibility testing against S. aureus , it is imperative that diagnostic laboratories use well-standardized methods and have a framework for detecting reduced vancomycin susceptibility in S. aureus .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to the difficulties on detecting these strains, vancomycin failures have been increasingly reported in deep-seated infections.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Indeed, S. aureus within the range of susceptibility, with vancomycin MICs > 1 and ≤ 2 μg/ml have been more frequently associated with the hVISA phenotype.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“These global homeostatic changes appear to lead to a reduced autolytic activity with thickened cell wall and an increase amount of free D-Ala-D-Ala dipeptides with less peptidoglycan cross-linking (101, 104).”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Phenotypically, hVISA/VISA strains exhibit distinct metabolic characteristics that may include i) increase in fructose utilization, ii) increased fatty acid metabolism, iii) impaired acetate metabolism and tricarboxylic acid cycle, iv) decrease in glutamate availability, and iv) increase expression of cell wall synthesis genes.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“As the “resistant” subpopulation is difficult to identify, detection of hVISA becomes very challenging and some S. aureus strains reported as “susceptible” to vancomycin by standard susceptibility testing may still exhibit this phenotype (101).”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“In addition, VISA strains bind vancomycin more avidly than their non –VISA counterparts, however, diffusion of the antibiotic molecule into the inner part of the cell wall appears to be impaired.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Finally, a striking feature of many hVISA/VISA strains is the ability to revert from one phenotype to another (or even to a fully vancomycin susceptible phenotype) in the absence of vancomycin exposure.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 405
Marchese, A. E., Balistreri, G., Tonoli, E., Debbia, E. A., & Schito, G. C. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.866-869.2000 · Cited by 112
Decreased Teicoplanin Susceptibility of Methicillin-Resistant Strains of Staphylococcus aureus
Mainardi, J., Shlaes, D. M., Goering, R. V., Shlaes, J. H., Acar, J. F., & Goldstein, F. W. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1646 · Cited by 111
Jacqueline, C., Caillon, J., Mabecque, V. L., Miegeville, A.-F., Hamel, A., Bugnon, D., Ge, J. Y., & Potel, G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01242-06 · Cited by 111
Chuard, C. R. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/39.5.603 · Cited by 109
Zinn, C. S., Westh, H., Rosdahl, V. T., & Sarisa Study Group (2004) · Microbial Drug Resistance · doi:10.1089/1076629041310055 · Cited by 109
Jansen, A., Türck, M., Szekat, C., Nagel, M., Clever, I., & Bierbaum, G. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.02.002 · Cited by 108
Staphylococcus aureus protein A activates TACE through EGFR‐dependent signaling
Gómez, M. I., Seaghdha, M. O., & Prince, A. S. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601554 · Cited by 108
Management of bone and joint infections due to Staphylococcus aureus
Davis, J. S. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00982.x · Cited by 108
Tenover, F. C., Mohammed, M. J., Stelling, J. M., O'Brien, T., & Williams, R. J. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.241-250.2001 · Cited by 107
Presence of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Germany
Bierbaum, G., Fuchs, K., Lenz, W., Szekat, C., & Sahl, H. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050380 · Cited by 106
Horne, K., Howden, B. P., Grabsch, E. A., Graham, M., Ward, P. B., Xie, S., Mayall, B. C., Johnson, P. D. R., & Grayson, M. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01365-08 · Cited by 105
Self-citationTsuji, B. T., Rybak, M. J., Cheung, C. M., Amjad, M., & Kaatz, G. W. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.10.021 · Cited by 105
Kornblum, J. S., Hartman, B. J., Novick, R. P., & Tomasz, A. (1986) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02013311 · Cited by 104
Boyle‐Vavra, S., Labischinski, H., Ebert, C. C., Kerstin Ehlert, B., & Daum, R. S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.280-287.2001 · Cited by 101
Studies on the mode of action of vancomycin
Reynolds, P. E. (1961) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(61)90698-9 · Cited by 99
Guérin, F., Buu-Hoï, A., Mainardi, J., Kac, G., Colardelle, N., Vaupré, S., Gutmann, L., & Podglajen, I. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.8.2985-2988.2000 · Cited by 98
Sheagren, J. N. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405313102206 · Cited by 98
Sader, H. S., Rhomberg, P. R., & Jones, R. N. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-09 · Cited by 97
Yusof, A., Engelhardt, A., Karlsson, A., Bylund, L., Vidh, P., Mills, K., Wootton, M., & Walsh, T. R. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00265-08 · Cited by 97
Robert, J., Bismuth, R., & Jarlier, V. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki486 · Cited by 96
Maclayton, D. O., Suda, K. J., Coval, K. A., York, C. B., & Garey, K. W. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.003 · Cited by 96
Emergence in Asian Countries of Staphylococcus aureus with Reduced Susceptibility to Vancomycin
Song, J., Hiramatsu, K., Suh, J. Y., Ko, K. S., Ito, T., Kapi, M., Kiem, S., Ys, K., Oh, W. S., Peck, K. R., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4926-4928.2004 · Cited by 95
Denis, O. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf142 · Cited by 92
Verdier, I., Durand, G., Bes, M., Taylor, K. L., Lina, G., Vandenesch, F., Fattom, A., & Étienne, J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01572-06 · Cited by 91
Vancomycin resistant Staphylococcus aureus in the United States
Woodford, N. (2002) · Weekly releases (1997–2007) · doi:10.2807/esw.06.28.01913-en · Cited by 91
Shlaes, D. M., Shlaes, J. H., Vincent, S., Etter, L., Fey, P. D., & Goering, R. V. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2432 · Cited by 90
Yin, S., Daum, R. S., & Boyle‐Vavra, S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.336-343.2006 · Cited by 90
Tsuji, B. T., Rybak, M. J., Lau, K. L., & Sakoulas, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00671-06 · Cited by 90
Boyle‐Vavra, S. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.5.617 · Cited by 88
Structure of the linkage units between ribitol teichoic acids and peptidoglycan
Kojima, N., Araki, Y., & Ito, E. (1985) · Journal of Bacteriology · doi:10.1128/jb.161.1.299-306.1985 · Cited by 86
On the Secondary and Tertiary Structure of Murein
Labischinski, H., Barnickel, G., Bradaczek, H., & Giesbrecht, P. (1979) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1979.tb12949.x · Cited by 86
Pinho, M. G., de LENCASTRE, H., & Tomasz, A. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.4.1074-1079.2000 · Cited by 85
Pereira, P. M., Filipe, S. R., Tomasz, A., & Pinho, M. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00431-07 · Cited by 85
Iizawa, Y., Nagai, J., Ishikawa, T., Hashiguchi, S., Nαkαo, M., Miyake, A., & Okonogi, K. (2004) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-004-0309-3 · Cited by 84
Isolation in Brazil of NosocomialStaphylococcus aureusWith Reduced Susceptibility to Vancomycin
Oliveira, G. A., Dell'aquila, A., Masiero, R. L., Levy, C. E., Gomes, M. S., Cui, L., Hiramatsu, K., & Mamizuka, E. M. (2001) · Infection Control and Hospital Epidemiology · doi:10.1086/501932 · Cited by 84
Sancak, B., Erciş, S., Menemenlioğlu, D., Çolakoğlu, Ş., & Hasçelik, G. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki272 · Cited by 83
An Elevated Mutation Frequency Favors Development of Vancomycin Resistance in Staphylococcus aureus
Schaaff, F., Reipert, A., & Bierbaum, G. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3540-3548.2002 · Cited by 83
Role of fem factors in methicillin resistance
Berger‐Bächi, B., & Tschierske, M. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80048-4 · Cited by 81
Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00869-07 · Cited by 81
Ogston, A. (1882) · PubMed · Cited by 81
Tamber, S., & Cheung, A. L. (2008) · Infection and Immunity · doi:10.1128/iai.00859-08 · Cited by 80
Hubert, S. K., Mohammed, J. M., Fridkin, S. K., Gaynes, R. P., McGowan, J. E., & Tenover, F. C. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.11.3590-3593.1999 · Cited by 79
Trotonda, M. P., Xiong, Y.-Q., Memmi, G., Bayer, A. S., & Cheung, A. L. (2008) · The Journal of Infectious Diseases · doi:10.1086/595740 · Cited by 79
Reipert, A., Kerstin Ehlert, B., Kast, T., & Bierbaum, G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.568-576.2003 · Cited by 79
Pieper, R., Bunai, C. L., Mongodin, E. F., Parmar, P. P., Huang, S., Clark, D. J., Fleischmann, R. D., Gill, S. R., & Peterson, S. N. (2006) · PROTEOMICS · doi:10.1002/pmic.200500764 · Cited by 78
Diagnosis and management of Staphylococcus aureus bacteraemia
MITCHELL, D. H., & Howden, B. P. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00977.x · Cited by 78
Self-citationFinan, J. E., Archer, G. L., Pucci, M. J., & Climo, M. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3070-3075.2001 · Cited by 77
Leonard, S. N., Rossi, K., Newton, K. L., & Rybak, M. J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn520 · Cited by 77
Neoh, H., Hori, S., Komatsu, M., Oguri, T., Takeuchi, F., Cui, L., & Hiramatsu, K. (2007) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-6-13 · Cited by 76
Allen, N. E., LeTourneau, D. L., & Hobbs, J. N. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.66 · Cited by 76
Koprivnjak, T., Weidenmaier, C., Peschel, A., & Weiss, J. P. (2008) · Infection and Immunity · doi:10.1128/iai.01705-07 · Cited by 76
Intermediate Vancomycin Susceptibility in a Community-associated MRSA Clone
Graber, C. J., Wong, M. K., Carleton, H. A., Perdreau‐Remington, F., Haller, B. L., & Chambers, H. F. “. (2007) · Emerging infectious diseases · doi:10.3201/eid1303.060960 · Cited by 75
Maor, ., Rahav, G., Belausov, N., Ben-David, D., Smollan, G., & Keller, N. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01262-06 · Cited by 75
Sobral, R. G., Jones, A. E., Etages, S. G. D., Dougherty, T. J., Peitzsch, R. M., Gaasterland, T., Ludovice, A. M., de LENCASTRE, H., & Tomasz, A. (2006) · Journal of Bacteriology · doi:10.1128/jb.01439-06 · Cited by 74
Koehl, J. L., Muthaiyan, A., Jayaswal, R. K., Kerstin Ehlert, B., Labischinski, H., & Wilkinson, B. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3749-3757.2004 · Cited by 74
Teicoplanin Stress-Selected Mutations Increasing ς B Activity in Staphylococcus aureus
Bischoff, M., & Berger‐Bächi, B. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1714-1720.2001 · Cited by 73
Schulthess, B., Meier, S., Homerová, D., Goerke, C., Wolz, C., Kormanec, J., Berger‐Bächi, B., & Bischoff, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01255-08 · Cited by 72
McCallum, N., Karaüzüm, H., Getzmann, R., Bischoff, M., Majcherczyk, P. A., Berger‐Bächi, B., & Landmann, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00073-06 · Cited by 72
Chambers, H. F. “. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.884-888.2005 · Cited by 72
de Lassence, A., Hidri, N., Timsit, J., Joly‐Guillou, M., Thiéry, G., Boyer, A., Lablee, P., Blivet, A., Kalinowski, H., Martin, Y., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/498898 · Cited by 72
Lodise, T. P., Miller, C. D., Graves, J. P., Evans, A. M., Graffunder, E. M., Helmecke, M. R., & Stellrecht, K. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn329 · Cited by 72
Inactivation of the Methicillin Resistance Gene mecA in Vancomycin-Resistant Staphylococcus aureus
Sieradzki, K., Wu, S. W., & Tomasz, A. (1999) · Microbial Drug Resistance · doi:10.1089/mdr.1999.5.253 · Cited by 71
Burnie, J., Matthews, R., Jiman-Fatami, A., Gottardello, P., Hodgetts, S. J., & D’Arcy, S. (2000) · Clinical Infectious Diseases · doi:10.1086/314035 · Cited by 70
Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus
Ruzin, A. V., Severin, A. I., Moghazeh, S. L., Étienne, J., Bradford, P. A., Projan, S. J., & Shlaes, D. M. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(03)00028-x · Cited by 70
Grabs, A. J., & Lord, R. S. A. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04563.x · Cited by 70
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
Streit, J. M., Sader, H. S., Fritsche, T. R., & Jones, R. N. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.03.004 · Cited by 69
Staphylococcus aureus infective endocarditis: diagnosis and management guidelines
Murray, R. J. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00978.x · Cited by 68
Kim, M., Hwang, S., Pyo, Y.-J., Mun, H.-M., & Pai, C. H. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1376-1380.2002 · Cited by 68
Holmes, R. L., & Jorgensen, J. H. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00945-07 · Cited by 68
García-de-la-Mària, C., Marco, F., Armero, Y., Soy, D., Moreno, A., del Rı́o, A., Almela, M., Cervera, C., Ninot, S. P. I., Falces, C., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01011-09 · Cited by 68
Wootton, M., MacGowan, A. P., & Walsh, T. R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00678-06 · Cited by 68
Jevitt, L. A., Smith, A. J., Williams, P. P., Raney, P. M., McGowan, J. E., & Tenover, F. C. (2003) · Microbial Drug Resistance · doi:10.1089/107662903322762833 · Cited by 68
Lefort, A., Pavie, J., Garry, L., Chau, F., & Fantin, B. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1061-1064.2004 · Cited by 67
SarT Influences sarS Expression in Staphylococcus aureus
Schmidt, K. A., Manna, A. C., & Cheung, A. L. (2003) · Infection and Immunity · doi:10.1128/iai.71.9.5139-5148.2003 · Cited by 67
Portolés, M., Kiser, K. B., Bhasin, N., Chan, K. H., & Lee, J. C. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.917-923.2001 · Cited by 67
Emergence of vancomycin-intermediate Staphylococcus species in southern India
Menezes, G. A., Harish, B. N., Sujatha, S., Vinothini, K., & Parija, S. C. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47829-0 · Cited by 66
Alós, J.-I., García-Cañas, A., García-Hierro, P., & Salvanés, F. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn246 · Cited by 66
Tenover, F. C., Sinner, S. W., Segal, R. E., Huang, V., Alexandre, S. S., McGowan, J. E., & Weinstein, M. P. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.12.010 · Cited by 65
Khosrovaneh, A., RIEDERER, K. M., Saeed, S., Tabriz, M. S., Shah, A. R., Hanna, M., Sharma, M., Johnson, L. B., Fakih, M. G., & Khatib, R. (2004) · Clinical Infectious Diseases · doi:10.1086/383036 · Cited by 65
Chesneau, O., Morvan, A., & Solh, N. E. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.6.887 · Cited by 65
Vaudaux, P. E. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.2.163 · Cited by 64
Strain dependence of the cell wall-damage induced stimulon in Staphylococcus aureus
McCallum, N., Spehar, G., Bischoff, M., & Berger‐Bächi, B. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.06.008 · Cited by 63
A highly vancomycin-resistant laboratory mutant ofStaphylococcus aureus
Sieradzki, K., & Tomasz, A. (1996) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1996.tb08424.x · Cited by 62
Bobin-Dubreux, S., Reverdy, M. E., Nervi, C., Rougier, M., Bolmström, A., Vandenesch, F., & Étienne, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.349-352.2001 · Cited by 62
Nucleotide Substitutions in Staphylococcus aureus Strains, Mu50, Mu3, and N315
Ohta, T. (2004) · DNA Research · doi:10.1093/dnares/11.1.51 · Cited by 62
O’Neill, A. J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf118 · Cited by 62
Brunet, F. P., Vedel, G., Dreyfus, F., Vaxelaire, J. F., Giraud, T., Schremmer, B., & Monsallier, J. F. (1990) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963643 · Cited by 60
Garnier, F., Chainier, D., Walsh, T. R., Karlsson, A., Bolmström, A., Grélaud, C., Mounier, M., Denis, F., & Ploy, M.-C. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki413 · Cited by 60
Cha, R., & Rybak, M. J. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00119-6 · Cited by 59
Drummelsmith, J., Winstall, É., Bergeron, M. G., Poirier, G. G., & Ouellette, M. (2007) · Journal of Proteome Research · doi:10.1021/pr070521m · Cited by 59
Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue
Roberts, S., & Chambers, S. T. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00983.x · Cited by 58
Marco, F., de la Mària, C. G., Armero, Y., Amat, E., Soy, D., Moreno, A., del Rı́o, A., Almela, M., Mestres, C. A., Gatell, J. M., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00510-07 · Cited by 58
Penicillin-Binding Protein 1 of Staphylococcus aureus Is Essential for Growth
Wada, A., & Watanabe, H. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.10.2759-2765.1998 · Cited by 56
Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea
Kim, H. B., Park, W. B., Lee, K. D., Choi, Y. J., Park, S., Oh, M., Kim, E.-C., & Choe, K. W. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.6.2279-2281.2003 · Cited by 56
Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals
Turnidge, J. D., Nimmo, G. R., Francis, G., & on behalf of the Australian Group on Antimicrobial Resistance (AGAR) (1996) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1996.tb101350.x · Cited by 56
Sieradzki, K., & Tomasz, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.527-533.2006 · Cited by 55
Vancomycin-Intermediate Staphylococcus aureus in a Home Health-Care Patient
Hageman, J. C., Pegues, D. A., Jepson, C., Bell, R. L., Guinan, M. E., Ward, K. W., Cohen, M. D., Hindler, J. A., Tenover, F. C., McAllister, S. K., et al. (2001) · Emerging infectious diseases · doi:10.3201/eid0706.010618 · Cited by 55
TcaR, a Putative MarR-Like Regulator of sarS Expression
Holmes, N., Bischoff, M., Maki, H., Wada, A., & Berger‐Bächi, B. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.10.2966-2972.2004 · Cited by 55
Howden, B. P. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00986.x · Cited by 54
Self-citationWard, P. B., Johnson, P. D. R., Grabsch, E. A., Mayall, B. C., & Grayson, M. L. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143681.x · Cited by 54
Self-citationRisley, A., Loughman, T., Cywes‐Bentley, C., Foster, T. J., & Lee, J. C. (2007) · The Journal of Infectious Diseases · doi:10.1086/520932 · Cited by 53
Renzoni, A., Barras, C., François, P., Charbonnier, Y., Huggler, E., Garzoni, C., Kelley, W. L., Majcherczyk, P. A., Schrenzel, J., Lew, D. P., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-06 · Cited by 53
Renzoni, A., François, P., Li, D., Kelley, W. L., Lew, D. P., Vaudaux, P. E., & Schrenzel, J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.2958-2965.2004 · Cited by 53
Avison, M. B. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.255 · Cited by 52
Plipat, N., Livni, G., Bertram, H. C., & Thomson, R. B. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.5.2494-2496.2005 · Cited by 52
Sobral, R. G., Ludovice, A. M., de LENCASTRE, H., & Tomasz, A. (2006) · Journal of Bacteriology · doi:10.1128/jb.188.7.2543-2553.2006 · Cited by 52
Καντζάνου, Μ. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.5.729 · Cited by 51
Tsuji, B. T., von Eiff, C., Kelchlin, P. A., Forrest, A., & Smith, P. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01254-07 · Cited by 51
Hirschwerk, D. A., Ginocchio, C. C., Bythrow, M., & Condon, S. (2006) · Infection Control and Hospital Epidemiology · doi:10.1086/502688 · Cited by 50
Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators
Chambers, S. T. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00980.x · Cited by 50
Diagnosis and management of staphylococcal infections of vascular grafts and stents
Chambers, S. T. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00981.x · Cited by 50
Tillotson, G., Draghi, D. C., Sahm, D. F., Tomfohrde, K. M., del Fabro, T., & Critchley, I. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn149 · Cited by 50
Schwaber, M. J., Wright, S. B., Carmeli, Y., Venkataraman, L., DeGirolami, P. C., Gramatikova, A., Perl, T. M., Sakoulas, G., & Gold, H. S. (2003) · Emerging infectious diseases · doi:10.3201/eid0906.030001 · Cited by 49
Reverdy, M. E., Jarraud, S., Bohin-Duhreux, S., Buret, E., Girardo, P., Lina, G., Vandenesch, F., & Étienne, J. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1198-743x.2001.00256.x · Cited by 49
Aeschlimann, J. R., Hershberger, E., & Rybak, M. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1914 · Cited by 48
Boyle‐Vavra, S., Challapalli, M., & Daum, R. S. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.2036-2039.2003 · Cited by 48
Oscarsson, J. (2005) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2005.05.003 · Cited by 47
Nelson, J. L., Rice, K. C., Slater, S. R., Fox, P. M., Archer, G. L., Bayles, K. W., Fey, P. D., Kreiswirth, B. N., & Somerville, G. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01057-06 · Cited by 47
Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus
Howe, R. A., Wootton, M., Walsh, T. R., Bennett, P. M., & MacGowan, A. P. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.5.675 · Cited by 46
Fournier, B., & Klier, A. F. (2004) · Microbiology · doi:10.1099/mic.0.27194-0 · Cited by 46
Sobral, R. G., & Tomasz, A. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0068-2019 · Cited by 45
Cartolano, G.-L., Cheron, M., Benabid, D., Leneveu, M., & Boisivon, A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00830.x · Cited by 44
In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe
Jansen, W. T. M., Verel, A., Verhoef, J., & Milatović, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00100-07 · Cited by 44
Rybak, M. J., Leonard, S. N., Rossi, K. L., Cheung, C. M., Sader, H. S., & Jones, R. N. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01981-08 · Cited by 44
Staphylococcus aureus growth and type 5 capsular polysaccharide production in synthetic media
Stringfellow, W. T., Dassy, B., Lieb, M., & Fournier, J. M. (1991) · Applied and Environmental Microbiology · doi:10.1128/aem.57.2.618-621.1991 · Cited by 42
Glycopeptide resistance in Staphylococcus aureus: is it a real threat?
Gemmell, C. G. (2004) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-004-0307-5 · Cited by 42
Endocarditis Caused byStaphylococcus aureuswith Reduced Susceptibility to Vancomycin
Woods, C. W., Cheng, A. C., Fowler, V. G., Moorefield, M., Frederick, J., Sakoulas, G., Meka, V. G., Tenover, F. C., Zwadyk, P., & Wilson, K. H. (2004) · Clinical Infectious Diseases · doi:10.1086/383027 · Cited by 42
Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system
Bowker, K. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl311 · Cited by 42
Andrade-Baiocchi, S., Tognim, M. C. B., Baiocchi, O. C. G., & Sader, H. S. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00511-4 · Cited by 41
Ike, Y., Arakawa, Y., Ma, X., Tatewaki, K., Nagasawa, M., Tomita, H., Tanimoto, K., & Fujimoto, S. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.12.4445-4451.2001 · Cited by 40
Delgado, A., Riordan, J. T., Lamichhane-Khadka, R., Winnett, D. C., Ramos, J. J., Robinson, K., O’Brien, F. G., Cantore, S. A., & Gustafson, J. E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02437-06 · Cited by 40
van Griethuysen, A. J., Veen, A. V. '., Buiting, A. G. M., Walsh, T. R., & Kluytmans, J. A. J. W. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.6.2487-2491.2003 · Cited by 40
Modern management of portal hypertension
Lubel, J., & Angus, P. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2004.00739.x · Cited by 39
Naimi, T. S., Anderson, D., O'Boyle, C., Boxrud, D. J., Johnson, S. K., Tenover, F. C., & Lynfield, R. (2003) · Clinical Infectious Diseases · doi:10.1086/375228 · Cited by 39
Mackenzie, F. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf191 · Cited by 39
Kosowska-Shick, K., Ednie, L. M., McGhee, P., Smith, K., Todd, C. D., Wehler, A., & Appelbaum, P. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01073-08 · Cited by 39
Huang, Y., Hsiao, C.-H., Liao, C., Lee, C., & Hsueh, P. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01844-07 · Cited by 39
Cross-linking and O-Acetylation of Newly Synthesized Peptidoglycan in Staphylococcus aureus H
Snowden, M. A., Perkins, H. R., Wyke, A. W., Hayes, M. V., & Ward, J. B. (1989) · Microbiology · doi:10.1099/00221287-135-11-3015 · Cited by 39
A case of vancomycin-resistant enterococcal endocarditis.
Ferraz, V., Dusé, A. G., Kassel, M., Black, A. D., Ito, T., & Hiramatsu, K. (2000) · PubMed · Cited by 39
What makes resistance to methicillin heterogeneous?
Rohrer, S., Maki, H., & Berger‐Bächi, B. (2003) · Journal of Medical Microbiology · doi:10.1099/jmm.0.05176-0 · Cited by 38
Renzoni, A., Kelley, W. L., Barras, C., Monod, A., Huggler, E., François, P., Schrenzel, J., Studer, R., Vaudaux, P. E., & Lew, D. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01287-08 · Cited by 38
Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus
Hageman, J. C., Patel, J. B., Franklin, P., Miscavish, K., McDougal, L. K., Lonsway, D. R., & Khan, F. N. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.005 · Cited by 37
Salanitri, J., Kalff, V., KELLY, M. J., Holsworth, L., Williams, T. J., & Snell, G. I. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2004.00746.x · Cited by 37
Rose, W. E., Leonard, S. N., Rossi, K. L., Kaatz, G. W., & Rybak, M. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-08 · Cited by 37
Fitzgibbon, M. M., Rossney, A. S., & O'Connell, B. C. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00836-07 · Cited by 37
Warren, R. E., Harvey, G., Carr, R., Ward, D., & Doroshenko, A. I. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01870.x · Cited by 36
Huang, Y., Liao, C., Teng, L., & Hsueh, P. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01888.x · Cited by 35
Verdier, I., Reverdy, M. E., Étienne, J., Lina, G., Bes, M., & Vandenesch, F. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1024-1027.2004 · Cited by 35
Voß, A., Mouton, J. W., van Elzakker, E. P., Hendrix, R., Goessens, W. H. F., Kluytmans, J. A. J. W., Krabbe, P. F. M., de Neeling, A. J., Sloos, J. H., Öztoprak, N., et al. (2007) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-6-9 · Cited by 34
Leonard, S. N., & Rybak, M. J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn439 · Cited by 32
Pina, P., Marliere, C., Vandenesch, F., Bedos, J. P., Étienne, J., & Allouch, P. (2000) · Clinical Infectious Diseases · doi:10.1086/317464 · Cited by 32
Bennett, J. W., Murray, C. K., Holmes, R. L., PATTERSON, J. E., & Jorgensen, J. H. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.11.002 · Cited by 31
Marlowe, E. M., Cohen, M. D., Hindler, J. F., Ward, K. W., & Bruckner, D. A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2637-2639.2001 · Cited by 31
Poutrel, B., Rainard, P., & Sarradin, P. (1997) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.4.3.275-278.1997 · Cited by 30
Backo, M., Gaenger, E., Burkart, A. D., Chai, Y. L., & Bayer, A. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.10.2565 · Cited by 28
Munckhof, W., Kleinschmidt, S. L., & Turnidge, J. D. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.08.009 · Cited by 28
Heterogeneous resistance to vancomycin in Staphylococcus aureus
Howe, R. A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.130 · Cited by 28
Staphylococcus aureus—Probing for Host Weakness?
Camargo, I. L. B. D. C., & Gilmore, M. S. (2008) · Journal of Bacteriology · doi:10.1128/jb.00043-08 · Cited by 27
Ju, O., Woolley, M., & Gordon, D. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0063-1 · Cited by 27
Autolytic Properties of Glycopeptide-Intermediate Staphylococcus aureus Mu50
Utaida, S., Pfeltz, R. F., Jayaswal, R. K., & Wilkinson, B. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1541-1545.2006 · Cited by 27
Diagnosis and management of catheter‐related bloodstream infections due to Staphylococcus aureus
Gosbell, I. B. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00979.x · Cited by 27
Grimison, P., Goldstein, D., Schneeweiss, J., & Murray, N. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2004.00757.x · Cited by 25
Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada
Webster, D., Rennie, R. P., Brosnikoff, C., Chui, L., & Brown, C. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.07.007 · Cited by 25
Treatment of Vancomycin-intermediate Staphylcoccus aureus Endocarditis with Linezolid
Leung, K. T., Tong, M. K. H., Siu, Y.-P., Lam, C. S., Ng, H., & Lee, H. K. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410015907 · Cited by 24
Rohrer, S., & Berger‐Bächi, B. (2003) · Microbiology · doi:10.1099/mic.0.26315-0 · Cited by 24
The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland
Krzysztoń-Russjan, J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf252 · Cited by 23
Nonhoff, C., Denis, O., & Struelens, M. J. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01060.x · Cited by 22
Low-level vancomycin resistance in Staphylococcus aureus?an Australian perspective
Howden, B. P., Ward, P. B., Johnson, P. D. R., Charles, P. G. P., & Grayson, M. L. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1261-y · Cited by 22
Self-citationBernard, L., Vaudaux, P. E., Rohner, P., Huggler, E., Armanet, M., Pittet, D., Lew, D. P., & Schrenzel, J. (2004) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2004.01.012 · Cited by 21
Tsuji, B. T., Harigaya, Y., Lesse, A. J., Sakoulas, G., & Mylotte, J. M. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.01.028 · Cited by 21
Rybak, M. J., Cha, R., Cheung, C. M., Meka, V. G., & Kaatz, G. W. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.09.005 · Cited by 21
Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore
Sng, L., Koh, T. H., Wang, G. C. Y., Hsu, L. Y., Kapi, M., & Hiramatsu, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.11.001 · Cited by 21
Fox, P. M., Climo, M. W., & Archer, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01060-06 · Cited by 21
Mallaval, F. O., Carricajo, A., Delavenna, F., Recule, C., Fonsale, N., Manquat, G., Raffenot, D., Rogeaux, O., Aubert, G., & Tous, J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00878.x · Cited by 20
Tallent, S. M., Bischoff, T., Climo, M. W., Ostrowsky, B. E., Wenzel, R. P., & Edmond, M. B. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.6.2249-2250.2002 · Cited by 19
Treatment ofStaphylococcus aureusinfections: new issues, emerging therapies and future directions
Bishop, E. J., & Howden, B. P. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.1.1 · Cited by 19
Self-citationNishi, H., Komatsuzawa, H., Yamada, S., Fujiwara, T., Ohara, M., Ohta, K., Sugiyama, M., Ishikawa, T., & Sugai, M. (2003) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2003.tb03466.x · Cited by 17
Emergence of Vancomycin-IntermediateStaphylococcus aureusandS. sciuri, Greece
Tsakris, A., Papadimitriou, E., Douboyas, J., Stylianopoulou, F., & Manolis, E. N. (2002) · Emerging infectious diseases · doi:10.3201/eid0805.010387 · Cited by 16
Manquat, G., Croizé, J., Stahl, J. ‐., Meyran, M., Hirtz, P., & Micoud, M. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/29.6.731 · Cited by 16
O’Neill, A. J., & Chopra, I. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1484-1485.2003 · Cited by 13
An infection with linezolid-resistant S. aureus in a patient with left ventricular assist system
Kola, A., Kirschner, P., Gohrbandt, B., Chaberny, I. F., Mattner, F., Strüber, M., Gastmeier, P., & Suerbaum, S. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540601071875 · Cited by 13
Clinicians' attitudes to clinical practice guidelines
Johnson, D. W. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05234.x · Cited by 12
Muthaiyan, A., Jayaswal, R. K., & Wilkinson, B. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.623-625.2004 · Cited by 12
Effect of teicoplanin and vancomycin on Staphylococcus aureus ultrastructure.
Filice, G., Lanzarini, P., Orsolini, P., Soldini, L., Perversi, L., Carnevale, G., Comolli, G., & Castelli, F. (1990) · PubMed · Cited by 12
Piérard, D., Vandenbussche, H., Verschraegen, I., & Lauwers, S. (2004) · Pathologie Biologie · doi:10.1016/j.patbio.2004.07.016 · Cited by 11
Where has vancomycin-heterogeneously resistant Staphylococcus aureus gone?
Arakawa, Y., Ike, Y., & Nagasawa, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16068-6 · Cited by 11
Hüebner, J., Kropec, A., Engels, I., & Daschner, F. D. (2009) · Chemotherapy · doi:10.1159/000239002 · Cited by 11
Rose, W. E., Kaatz, G. W., Sakoulas, G., & Rybak, M. J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn037 · Cited by 11
Staphylococcal infections of the skin and skin structures.
Jn, S. (1985) · PubMed · Cited by 11
Sugino, Y., Iinumab, Y., Ichiyama, S., Ito, Y., Ohkawa, S., Nakashima, N., Shimokata, K., & Hasegawa, Y. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(00)00186-3 · Cited by 10
Takayama, Y., Hanaki, H., Irinoda, K., Kokubun, H., Yoshida, K., & Sunakawa, K. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00263-2 · Cited by 10
Ogston's Coccus: 102 years and still going strong.
Smith, G. (1982) · PubMed · Cited by 10
Tajima, Y., Komatsu, M., Ito, T., & Hiramatsu, K. (2007) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2007.05.020 · Cited by 9
SMITH, G. (1982) · Southern Medical Journal · doi:10.1097/00007611-198212000-00026 · Cited by 9
Manifestations of familial hypercholesterolaemia
Gillett, M. J., & Burnett, J. R. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2004.00779.x · Cited by 8
Jung, S.-I., Kiem, S., Lee, N. Y., Ys, K., Oh, W. S., Cho, H. L., Peck, K. R., & Song, J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1493-1495.2002 · Cited by 8
Wootton, M., Bennett, P. M., MacGowan, A. P., & Walsh, T. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3598-3599.2005 · Cited by 8
Glycopeptide-intermediate Staphylococcus aureus: rediscovery of an old problem?
Cercenado, E. (2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00130.x · Cited by 8
Murray, R. J., Sieunarine, K., Ward, P. B., & Pearman, J. W. (2004) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb06246.x · Cited by 8
The first glycopeptide-intermediate Staphylococcus aureus in Oman
Elhag, K. M., Jardani, A. K. A., Yaqubi, F. M. A., & Mohsin, N. F. (2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00036-5.x · Cited by 7
Research works printed but not linked: 1
- Ferraz, V., A. G. Duse, M. Kassel, A. D. Black, T. Ito, and K. Hiramatsu. 2000. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S. Afr. Med. J.90:1113.
Cited by
Sorted by citations
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Antimicrobial Resistance in ESKAPE Pathogens
Oliveira, D. M. P. D., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,243
Coagulase-Negative Staphylococci
Becker, K., Heilmann, C., & Peters, G. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-13 · Cited by 1,742
Methicillin-resistant Staphylococcus aureus
Lee, A. S., de LENCASTRE, H., Garau, J., Kluytmans, J. A. J. W., Malhotra‐Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,691
Metadata
- Authors
- Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L.
- Affiliations
- The University of Melbourne (AU)
- Monash University (AU)
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 23
- Issue
- 1
- Pages
- 99-139
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC2806658
- OpenAlex
- W2126915534
- Cited by
- 962
- References
- 406
- Citations by year
- 2026: 42 · 2025: 41 · 2024: 48 · 2023: 58 · 2022: 45 · 2021: 52 · 2020: 49 · 2019: 60 · 2018: 54 · 2017: 51 · 2016: 63 · 2015: 83 · 2014: 69 · 2013: 88 · 2012: 72
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin-intermediate Staphylococcus aureus, heterogeneous vancomycin-intermediate Staphylococcus aureus, reduced vancomycin susceptibility, glycopeptide resistance, cell wall thickening, agr gene, vancomycin susceptibility testing, treatment failure, host-pathogen interaction
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Treatment Outcome, Vancomycin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
